PMID- 35791415
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2230-326X (Electronic)
IS  - 2230-326X (Linking)
VI  - 12
DP  - 2022
TI  - Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our 
      Experience.
PG  - 177-185
LID - 10.2147/PTT.S367060 [doi]
AB  - PURPOSE: Dimethyl fumarate (DMF) is an oral formulation approved for the 
      treatment of moderate-to-severe psoriasis in adult patients requiring systemic 
      therapy. Here, we describe our clinical experience with DMF for 
      moderate-to-severe psoriasis in Spain. PATIENTS AND METHODS: This is a 
      retrospective study including 30 adult patients with moderate-to-severe psoriasis 
      under treatment with DMF between September 2018 and January 2020. Patients were 
      treated with DMF as per its Summary of Product Characteristics and the median 
      duration of treatment was 15 weeks (4-55 weeks). Psoriasis Area and Severity 
      Index (PASI) and body surface area (BSA) severity scales were evaluated from 
      baseline to week 36 and adverse events (AEs) developed during treatment were 
      described. RESULTS: The efficacy of DMF was assessed at week 8 and at week 36 (n 
      = 5), both PASI and BSA were 0. At week 24, median PASI showed a decrease in both 
      the last observation carried forward (LOCF; n = 23) and the observed cases (OC) 
      (n = 10): from 10 to 6 and from 10 to 1.5, respectively. Median BSA also showed a 
      decrease from 19 to 10 in LOCF and from 17 to 3 in OC. The most frequent AEs were 
      diarrhoea (40.0%), flushing (13.3%) and lymphopenia (3.3%). In 47.1% patients, 
      AEs have been solved by adjusting the DMF dose. Treatment discontinuation rate 
      due to AEs was 43.3%. CONCLUSION: Our clinical experience indicates that DMF 
      could be an effective and safe treatment for moderate-to-severe psoriasis in 
      adult patients.
CI  - (c) 2022 Roses Gibert et al.
FAU - Roses Gibert, Pau
AU  - Roses Gibert P
AD  - Dermatology Department, Araba University Hospital, Vitoria-Gasteiz, Spain.
FAU - de la Torre Gomar, Francisco Javier
AU  - de la Torre Gomar FJ
AD  - Dermatology Department, Araba University Hospital, Vitoria-Gasteiz, Spain.
FAU - Saenz Aguirre, Amaia
AU  - Saenz Aguirre A
AD  - Dermatology Department, Araba University Hospital, Vitoria-Gasteiz, Spain.
FAU - Gimeno Castillo, Javier
AU  - Gimeno Castillo J
AUID- ORCID: 0000-0002-3307-9005
AD  - Dermatology Department, Araba University Hospital, Vitoria-Gasteiz, Spain.
FAU - Gonzalez Perez, Ricardo
AU  - Gonzalez Perez R
AD  - Dermatology Department, Araba University Hospital, Vitoria-Gasteiz, Spain.
LA  - eng
PT  - Journal Article
DEP - 20220629
PL  - New Zealand
TA  - Psoriasis (Auckl)
JT  - Psoriasis (Auckland, N.Z.)
JID - 101709086
PMC - PMC9250788
OTO - NOTNLM
OT  - clinical experience
OT  - dimethyl fumarate
OT  - moderate-to-severe psoriasis
OT  - retrospective study
COIS- PRG has received honoraria as speaker from Almirall related to this work. JGC 
      reports grants from Almirall, during the conduct of the study. All other authors 
      have no conflicts of interest to declare in this work.
EDAT- 2022/07/07 06:00
MHDA- 2022/07/07 06:01
PMCR- 2022/06/29
CRDT- 2022/07/06 01:59
PHST- 2022/03/22 00:00 [received]
PHST- 2022/06/14 00:00 [accepted]
PHST- 2022/07/06 01:59 [entrez]
PHST- 2022/07/07 06:00 [pubmed]
PHST- 2022/07/07 06:01 [medline]
PHST- 2022/06/29 00:00 [pmc-release]
AID - 367060 [pii]
AID - 10.2147/PTT.S367060 [doi]
PST - epublish
SO  - Psoriasis (Auckl). 2022 Jun 29;12:177-185. doi: 10.2147/PTT.S367060. eCollection 
      2022.